Pharmaceuticals and Their Chokepoints
The Council on Foreign Relations released a 29,000‑word report detailing the United States’ deep reliance on China for active pharmaceutical ingredients (APIs) and key starting materials, even though finished generic drugs largely come from India, Europe, and the U.S. The analysis shows that over 80% of APIs for common medicines like amoxicillin are sourced from Chinese manufacturers, creating a hidden choke point in the supply chain. It also flags emerging therapeutic areas—such as monoclonal antibodies and synthetic DNA—where Chinese production is rapidly expanding. The report outlines a suite of policy options, urging executive agencies like HHS and Commerce to lead an industrial‑policy push for greater domestic resilience.
How Capital Costs Make It Near-Impossible to Be an Independent Physician
A new report highlights how soaring capital costs are pushing independent physicians out of business. Consolidation by hospital systems, insurers, and private‑equity firms has squeezed small practices, forcing them to seek expensive, often predatory financing. The analysis shows independent doctors...
Physician Shortages and Licensing
Physician shortages, especially in primary care, are driving long wait times and higher costs for Americans. Health policy analyst Lawson Mansell argues that the shortage is real, citing primary‑care visit delays as a proxy, and points to mismatches in residency...
Accelerating Into Fraud
MEDVi, a two‑person telehealth startup, is projected to generate $1.8 billion in 2026 by selling compounded GLP‑1 weight‑loss drugs through the white‑labeled OpenLoop platform. The company relies heavily on AI‑generated marketing, virtual doctors, and automated customer service to drive sales. A...